News Column

STERIS Corporation Announces Fiscal 2015 First Quarter Results

August 5, 2014

* Double digit growth in-line with expectations * The Company affirms its outlook for fiscal 2015 * Board of Directors increases quarterly dividend by two cents to $0.23 per share Mentor, Ohio (August 5, 2014) - STERIS Corporation (NYSE: STE) today announced financial results for its fiscal 2015 first quarter ended June 30, 2014.  Fiscal 2015 first quarter revenue increased 12% to $412.6 million compared with $367.7 million in the first quarter of fiscal 2014, driven by growth in the Company's Healthcare and Isomedix segments.  Organic revenue growth in the first quarter of fiscal 2015 was 3%. As reported, fiscal 2015 first quarter net income was $24.5 million, or $0.41 per diluted share, compared with net income of $32.3 million, or $0.54 per diluted share in the first quarter of fiscal 2014, which includes a $0.15 tax benefit associated with the Company's prior European restructuring effort. Adjusted earnings in the first quarter of fiscal 2015 increased to $0.54 per diluted share compared with $0.44 per diluted share in the first quarter of fiscal 2014.  Please refer to the attached schedules for additional information, including reconciliations of adjusted "non-GAAP financial measures" to reported results. "We are pleased to have a strong start to our fiscal year," said Walt Rosebrough, President and Chief Executive Officer of STERIS. "Revenue growth was in-line with our expectations as our consumables business exceeded forecast and offset a little softness in our capital equipment shipments.  We believe both of these trends are a matter of timing.  As a result, we anticipate that we will achieve our full year outlook of double digit revenue and adjusted earnings growth." Segment Results             Healthcare revenue in the quarter was $302.8 million, an increase of 17% compared with $258.9 million in the first quarter of fiscal 2014.  This growth was across the business, with service revenue growth of 43%, consumable revenue increases of 12% and capital equipment revenue was up 1%.  Healthcare revenue grew 4% organically excluding the IMS and Eschmann acquisitions.  As reported, operating income for the first quarter of fiscal 2015 was $18.0 million compared with operating income of $14.9 million in last year's first quarter.  Adjusted operating income was $29.7 million compared with $19.7 million in the prior year first quarter, driven by organic volume growth, product mix and acquisitions. Life Sciences first quarter revenue declined 2% to $58.6 million compared with $59.9 million in the first quarter of fiscal 2014.  While consumable revenue increased 6% and service revenue grew 9%, it was not enough to offset an 18% decline in capital equipment revenue, which tends to vary by quarter. Life Sciences first quarter fiscal 2015 operating income was $11.9 million compared with $12.5 million in last year's first quarter, primarily reflecting the decline in volume. Fiscal 2015 first quarter revenue for Isomedix Services was $51.2 million compared with $48.2 million in the same period last year, an increase of 6%. Operating income for the first quarter of fiscal 2015 increased to $16.2 million compared with $14.7 million in the first quarter of last year, as Isomedix continues to fill the recently expanded capacity. Cash Flow Net cash provided by operations for the first quarter of fiscal 2015 was $46.4 million, compared with $32.7 million last year.  Free cash flow (see note 1) for the first quarter of fiscal 2015 was $23.1 million, compared with $11.0 million in the prior year.  The improvement in free cash flow is primarily due to working capital improvements. Outlook Based upon current trends, the Company is affirming its original outlook for fiscal 2015, which includes revenue growth in the range of 15-17% and adjusted earnings per diluted share in the range of $2.78 to $2.91 for the full fiscal year.  Please see the Company's earnings release dated May 8, 2014 for a more detailed outlook. Dividend Announcement The Company also announced today that STERIS's Board of Directors has authorized a two cent increase in its quarterly dividend to $0.23 per common share, representing the ninth consecutive year of dividend increases.  The dividend is payable September 23, 2014 to shareholders of record at the close of business on August 26, 2014. Conference Call In conjunction with this release, STERIS Corporation management will host a conference call today at 10:00 a.m. Eastern time.  The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-800-369-8428 in the United States and Canada, and 1-773-799-3378 internationally, then referencing the password "STERIS". For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. Eastern time either over the Internet at www.steris-ir.com or via phone by calling 1-800-685-6364 in the United States and Canada, and 1-402-998-0553 internationally. About STERIS The mission of STERIS Corporation is to help our Customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit www.steris.com. (1)   Free cash flow is a non-GAAP number used by the Company as a measure to gauge its ability to fund future debt principal repayments, growth outside of core operations, repurchase common shares, and pay cash dividends.  Free cash flow is defined as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net, plus proceeds from the sale of property, plant, equipment and intangibles. STERIS's calculation of free cash flow may vary from other companies. The press release and referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward- looking information affecting or relating to the Company or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this press release and the referenced conference call, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "impact," "potential," "confidence," "improve," "optimistic," "deliver," "comfortable," "trend", and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described herein and in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in the press release, or the referenced conference call or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results. References to products and the consent decree are summaries only and should not be considered the specific terms of the decree or product clearance or literature. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward- looking statements include, without limitation, (a) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products or applications or business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning notices or letters, government investigations,  the outcome of any pending FDA requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect Company performance, results, prospects or value, (d) the potential of international unrest, economic downturn or effects of currencies, tax assessments, adjustments, or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with our business, industry or initiatives including, without limitation, the consent decree, or those matters described in our Form 10-K for the year ended March 31, 2014 and other securities filings, may adversely impact Company performance, results, prospects or value, (g) the possibility that anticipated financial results or benefits of recent acquisitions or of our restructuring efforts will not be realized or will be other than anticipated, (h) the effects of contractions in credit availability, as well as the ability of our Customers and suppliers to adequately access the credit markets when needed, and (i) those risks described in our securities filings including our Annual Report on Form 10-K for the year ended March 31, 2014, and other securities filings. Contact: Julie Winter, Director, Investor Relations at 440-392-7245. STERIS Fiscal 2015 First Quarter Financials: http://hugin.info/149217/R/1846453/643580.pdf This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Steris Corporation via GlobeNewswire [HUG#1846453]


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Thomson Reuters ONE


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters